Biotek-snakken — November 2023
-
Efter stort fald: Novos hjerte-kar-data har medvirket til comeback i flere sundhedsaktier https://www.proinvestor.com/investornyt/1081157/efter-stort-fald-novos-hjerte-kar-data-har-medvirket-til-comeback-i-flere-sundhedsaktier
-
BRIEF-Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease to European Medicines Agency
14:20 Nov 20 (Reuters) - Anavex Life Sciences Corp :
ANAVEX INITIATES REGULATORY SUBMISSION OF ORAL
BLARCAMESINE FOR
ALZHEIMER’S DISEASE TO EUROPEAN MEDICINES AGENCY (EMA)Source text for Eikon:
Further company coverage:(([email protected];))
-
Anavex Dialog med EMA om godkendelse af 2-73 i Alzheimer!!! https://www.proinvestor.com/boards/116834/
-
Xbrane Biopharma is focusing the development portfolio and introducing a cost-savings scheme
-
STENOCARE oplever et stærkere salg end forventet (budgetter vs. faktiske tal) i Australien og udvider nu sin tilstedeværelse med et nyt medicinsk cannabisolieprodukt.https://www.proinvestor.com/boards/116921
-
XBrane….der ryddes op, og nu gør de da i det mindste lidt for at vende skuden, men markedet er i første omgang
ikke begejstret.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind